注意缺陷多动障碍的神经反馈治疗:系统综述与Meta分析
本系统综述与Meta分析纳入38项平行组随机临床试验(2472名5至40岁临床诊断为注意缺陷多动障碍或过度运动综合征的参与者),评估神经反馈对核心症状和神经心理结局的疗效。可能盲法评估的注意缺陷多动障碍总症状严重程度未见显著改善(k=20;n=1214;SMD,0.04;95%CI,-0.10至0.18);仅在使用既定标准方案的试验中观察到小幅显著改善(k=9;n=681;SMD,0.21;95%CI,0.02至0.40),5项神经心理结局中仅加工速度显示小幅显著改善(k=15;n=909;SMD,0.35;95%CI,0.01至0.69)。总体而言,神经反馈在组水平上未显示出对注意缺陷多动障碍患者的临床或神经心理学意义获益。
要点
- 可能盲法评估的注意缺陷多动障碍总症状未见显著改善(SMD,0.04;95%CI,-0.10至0.18)。
- 使用既定标准方案的试验显示小幅显著改善(SMD,0.21;95%CI,0.02至0.40)。
- 5项神经心理结局中仅加工速度显示小幅显著改善(SMD,0.35;95%CI,0.01至0.69)。
核心结论
- 总体而言,神经反馈在组水平上未显示出对注意缺陷多动障碍患者具有临床或神经心理学意义的获益。
- 未来研究可关注使用标准神经反馈方案、测量加工速度以及利用包括神经影像技术在内的精准医学进展来识别可能获益的注意缺陷多动障碍个体。
研究设计与样本
- 研究为系统综述与Meta分析,检索PubMed(MEDLINE)、Ovid(PsycInfo、MEDLINE、Embase及Embase Classic)和Web of Science以及合格记录和相关系统综述的参考文献列表,检索截至2023年7月25日,无语言限制。
- 纳入标准为平行组随机临床试验,研究对象为任何年龄、临床诊断为注意缺陷多动障碍或过度运动综合征的参与者。
- 共纳入38项随机临床试验,2472名参与者,年龄5至40岁。
- 采用Cochrane偏倚风险工具2.0版评估随机临床试验。
- 使用Hedges g校正的标准化均数差(SMD)在随机效应Meta分析中合并所有合格结局。
主要发现
- 可能盲法评估的注意缺陷多动障碍总症状严重程度未见显著改善(k=20;n=1214;SMD,0.04;95%CI,-0.10至0.18)。
- 限制为使用既定标准方案的随机临床试验时,观察到小幅显著改善(k=9;n=681;SMD,0.21;95%CI,0.02至0.40)。
- 排除成人或限制为已确立皮层学习或自我调节的随机临床试验时,结果保持相似。
- 5项神经心理结局中,仅加工速度显示小幅显著改善(k=15;n=909;SMD,0.35;95%CI,0.01至0.69)。
- 异质性一般为低至中等。
关键数值与推荐
- 主要结局为首次干预后时间点评估的注意缺陷多动障碍总症状严重程度,重点关注可能或确定对治疗分配不知情的评估者报告。
- 次要结局为干预后及长期随访(即末次随访时间点之后)的注意力不集中和/或多动-冲动症状以及神经心理结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neurofeedback has been proposed for the treatment of attention-deficit/hyperactivity disorder (ADHD) but the efficacy of this intervention remains unclear. OBJECTIVE: To conduct a meta-analysis of randomized clinical trials (RCTs) using probably blinded (ie, rated by individuals probably or certainly unaware of treatment allocation) or neuropsychological outcomes to test the efficacy of neurofeedback as a treatment for ADHD in terms of core symptom reduction and improved neuropsychological outcomes. DATA SOURCES: PubMed (MEDLINE), Ovid (PsycInfo, MEDLINE, Embase + Embase Classic), and Web of Science, as well as the reference lists of eligible records and relevant systematic reviews, were searched until July 25, 2023, with no language limits. STUDY SELECTION: Parallel-arm RCTs investigating neurofeedback in participants of any age with a clinical ADHD or hyperkinetic syndrome diagnosis were included. DATA EXTRACTION AND SYNTHESIS: Standardized mean differences (SMDs) with Hedges g correction were pooled in random effects meta-analyses for all eligible outcomes. MAIN OUTCOMES AND MEASURES: The primary outcome was ADHD total symptom severity assessed at the first postintervention time point, focusing on reports by individuals judged probably or certainly unaware of treatment allocation (probably blinded). Secondary outcomes were inattention and/or hyperactivity-impulsivity symptoms and neuropsychological outcomes postintervention and at a longer-term follow-up (ie, after the last follow-up time point). RCTs were assessed with the Cochrane risk of bias tool version 2.0. RESULTS: A total of 38 RCTs (2472 participants aged 5 to 40 years) were included. Probably blinded reports of ADHD total symptoms showed no significant improvement with neurofeedback (k = 20; n = 1214; SMD, 0.04; 95% CI, -0.10 to 0.18). A small significant improvement was seen when analyses were restricted to RCTs using established standard protocols (k = 9; n = 681; SMD, 0.21; 95% CI, 0.02 to 0.40). Results remained similar with adults excluded or when analyses were restricted to RCTs where cortical learning or self-regulation was established. Of the 5 neuropsychological outcomes analyzed, a significant but small improvement was observed only for processing speed (k = 15; n = 909; SMD, 0.35; 95% CI, 0.01 to 0.69). Heterogeneity was generally low to moderate. CONCLUSIONS AND RELEVANCE: Overall, neurofeedback did not appear to meaningfully benefit individuals with ADHD, clinically or neuropsychologically, at the group level. Future studies seeking to identify individuals with ADHD who may benefit from neurofeedback could focus on using standard neurofeedback protocols, measuring processing speed, and leveraging advances in precision medicine, including neuroimaging technology.
引用
- Westwood SJ, Aggensteiner PM, Kaiser A, et al. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 39661381. doi:10.1001/jamapsychiatry.2024.3702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。